The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Agenus; OncXerna Therapeutics; Treos Bio; Verastem
Stock and Other Ownership Interests - Agenus; OncXerna Therapeutics; Treos Bio; Verastem
Consulting or Advisory Role - C4 Therapeutics
ONCX-NAV-G201: A phase 2 basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors—Colorectal Cancer Cohort (trial in progress).
 
Paul Eliezer Oberstein
Consulting or Advisory Role - AstraZeneca; Delcath Systems; Merck; QED Therapeutics; Rubius Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - Arcus Biosciences (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst)
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Merck
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); Codiak Biosciences (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Gritstone Bio (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); OncXerna Therapeutics (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Kerry Culm
Employment - Oncologie
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
Patents, Royalties, Other Intellectual Property - Patent on administration of IMGN632 and IMGN779
 
Valerie Chamberlain Santos
Employment - OncXerna Therapeutics
 
Andrew Koustenis
Employment - OncXerna Therapeutics; Verastem
Stock and Other Ownership Interests - Lilly
 
Colleen M. Mockbee
Employment - OncXerna Therapeutics
Leadership - OncXerna Therapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics; Krystal Biotech; Mirati Therapeutics; Rocket Pharma; Sarepta Therapeutics
Consulting or Advisory Role - Elevation Oncology; Partner Therapeutics
 
Hagop Youssoufian
No Relationships to Disclose
 
John C. Krauss
Research Funding - Abbvie (Inst); Abbvie (Inst); ACCRU (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance for Clinical Trials in Oncology (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Cardiff Oncology; Daiichi Sankyo/Arqule (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Isofol Medical (Inst); Novartis (Inst); NSABP FOUNDATION (Inst); NSABP Foundation (Inst); Pfizer (Inst); Tempest Therapeutics (Inst); Tempest Therapeutics (Inst)